Background: Alzheimer's disease (AD) and dementia are chronic diseases with progressive
deterioration of cognition, function, and behavior leading to severe disability and death. The …

Aducanumab has been approved by the US Food and Drug Administration for treatment of
Alzheimer's disease (AD). Clinicians require guidance on the appropriate use of this new …

Alzheimer's disease (AD) and other neurodegenerative diseases such as Parkinson's
disease (PD) and Huntington's disease (HD) are associated with progressive cognitive …

The hippocampus is generally reported as one of the regions most impacted by Alzheimer's
disease (AD) and is closely associated with memory function and orientation. Undirected …

Introduction Detecting functional decline from normal aging to dementia is relevant for
diagnostic and prognostic purposes. Therefore, the Amsterdam IADL Questionnaire (A-IADL …

Abstract Background The Clinical Dementia Rating-Sum of Boxes (CDR-SB) has been
proposed as a primary outcome for use in prodromal AD trials. However, the psychometric …

Impairment in instrumental activities of daily living (IADL) is an early clinical feature of
Alzheimer's disease (AD). The neurobiology underlying IADL disruptions is still unclear. We …

Alzheimer's disease (AD) is characterized by progressive deterioration of brain function
among elderly people. Studies revealed aberrant correlations in spontaneous blood oxygen …

Resumen BAZALAR-SILVA, Lorena; RUNZER-COLMENARES, Fernando M y PARODI,
José F. Asociación entre el estado nutricional según índice de masa corporal y deterioro …

Introduction In an attempt to capture clinically meaningful cognitive decline in early
dementia, we developed the Cognitive‐Functional Composite (CFC). We investigated the …